pharmadog
fetch the data · sniff the signal
© 2026 pharmadog.xyz
made by humans and a good dog
🐶
Retevmo · pharmadog
pharmadog › drugs › Retevmo
selpercatinib Marketed updated 2mo ago by Eli Lilly and Co 🔗 ChEMBL Approved
community read 0 votes
↑ 0 good boy ↓ 0 doghouse
Small molecule drug with a maximum clinical stage of Approval (across all indications), with 11 approved and 2 investigational indications.
indications investigational
NSCLC Breast Cancer Colorectal Cancer
targets Coiled-coil domain-containing protein 6/Tyrosine-protein kinase receptor RET Proto-oncogene tyrosine-protein kinase receptor Ret Kinesin-1 heavy chain/ Tyrosine-protein kinase receptor RET
News(0) no news has mentioned this drug yet
trade names
Retevmo, Retsevmo
MOA
Coiled-coil domain-containing protein 6/Tyrosine-protein kinase receptor RET inhibitor; Tyrosine-protein kinase receptor RET inhibitor; Kinesin-1 heavy chain/ Tyrosine-protein kinase receptor RET inhibitor
indication
Anaplastic Thyroid Cancer
Data sources
last refreshed just now
Found something off? report 🐶 something off?
Report a data issue Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.
cancel send
$LLY 1200.06 -1.14%
Patent cliff source: FDA Orange Book first barrier falls
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (56) Apr 10, 2039 patent US 10584124*PED Apr 10, 2039 patent US 10584124*PED Apr 10, 2039 patent US 10786489*PED Apr 10, 2039 patent US 10786489*PED Apr 10, 2039 patent US 12138250*PED Apr 10, 2039 patent US 12138250*PED Apr 10, 2039 patent US 12138250*PED Apr 10, 2039 patent US 12138250*PED Apr 10, 2039 patent US 12138250*PED Apr 10, 2039 patent US 12138250*PED Oct 10, 2038 composition US 10584124 Oct 10, 2038 composition US 10584124 Oct 10, 2038 formulation US 10786489 Oct 10, 2038 formulation US 10786489 Oct 10, 2038 method-of-use (U-3950) US 12138250 Oct 10, 2038 method-of-use (U-3949) US 12138250 Oct 10, 2038 method-of-use (U-3949) US 12138250 Oct 10, 2038 method-of-use (U-3450) US 12138250 Oct 10, 2038 method-of-use (U-3450) US 12138250 Oct 10, 2038 method-of-use (U-3949) US 12138250 Apr 10, 2038 patent US 10112942*PED Apr 10, 2038 patent US 10112942*PED Apr 10, 2038 patent US 10112942*PED Apr 10, 2038 patent US 10112942*PED Apr 10, 2038 patent US 10112942*PED Apr 10, 2038 patent US 10112942*PED Apr 10, 2038 patent US 10137124*PED Apr 10, 2038 patent US 10137124*PED Apr 10, 2038 patent US 10137124*PED Apr 10, 2038 patent US 10137124*PED Apr 10, 2038 patent US 10137124*PED Apr 10, 2038 patent US 10137124*PED Apr 10, 2038 patent US 10172851*PED Apr 10, 2038 patent US 10172851*PED Apr 10, 2038 patent US 10172851*PED Apr 10, 2038 patent US 10172851*PED Apr 10, 2038 patent US 10172851*PED Apr 10, 2038 patent US 10172851*PED Oct 10, 2037 composition US 10112942 Oct 10, 2037 composition US 10112942 Oct 10, 2037 composition US 10112942 Oct 10, 2037 composition US 10112942 Oct 10, 2037 composition US 10112942 Oct 10, 2037 composition US 10112942 Oct 10, 2037 method-of-use (U-3951) US 10137124 Oct 10, 2037 method-of-use (U-3951) US 10137124 Oct 10, 2037 method-of-use (U-3950) US 10137124 Oct 10, 2037 method-of-use (U-3951) US 10137124 Oct 10, 2037 method-of-use (U-3951) US 10137124 Oct 10, 2037 method-of-use (U-3951) US 10137124 Oct 10, 2037 method-of-use (U-3951) US 10172851 Oct 10, 2037 method-of-use (U-3951) US 10172851 Oct 10, 2037 method-of-use (U-3951) US 10172851 Oct 10, 2037 method-of-use (U-3450) US 10172851 Oct 10, 2037 method-of-use (U-3950) US 10172851 Oct 10, 2037 method-of-use (U-3951) US 10172851 FDA exclusivities (68) Nov 29, 2031 PED Pediatric (6mo bonus) Nov 29, 2031 PED Pediatric (6mo bonus) Nov 29, 2031 PED Pediatric (6mo bonus) Nov 29, 2031 PED Pediatric (6mo bonus) Nov 29, 2031 PED Pediatric (6mo bonus) Nov 29, 2031 PED Pediatric (6mo bonus) May 29, 2031 ODE* ODE* 4.9y $LLY 1200.06 -1.14%
$LLY 1200.06 -1.14%
$LLY 1200.06 -1.14%
$LLY 1200.06 -1.14%
$LLY 1200.06 -1.14%
$LLY 1200.06 -1.14%
May 29, 2031
ODE-484
Orphan Drug (7y)
4.9y
May 29, 2031 ODE-485 Orphan Drug (7y) 4.9y
May 29, 2031 ODE-487 Orphan Drug (7y) 4.9y
May 29, 2031 ODE-484 Orphan Drug (7y) 4.9y
May 29, 2031 ODE-485 Orphan Drug (7y) 4.9y
May 29, 2031 ODE-487 Orphan Drug (7y) 4.9y
May 29, 2031 ODE* ODE* 4.9y
May 29, 2031 ODE* ODE* 4.9y
May 29, 2031 ODE* ODE* 4.9y
Mar 21, 2030 PED Pediatric (6mo bonus) 3.7y
Mar 21, 2030 PED Pediatric (6mo bonus) 3.7y
Mar 21, 2030 PED Pediatric (6mo bonus) 3.7y
Mar 21, 2030 PED Pediatric (6mo bonus) 3.7y
Mar 21, 2030 PED Pediatric (6mo bonus) 3.7y
Mar 21, 2030 PED Pediatric (6mo bonus) 3.7y
Sep 21, 2029 ODE-412 Orphan Drug (7y) 3.2y
Sep 21, 2029 ODE* ODE* 3.2y
Sep 21, 2029 ODE-412 Orphan Drug (7y) 3.2y
Sep 21, 2029 ODE* ODE* 3.2y
Sep 21, 2029 ODE* ODE* 3.2y
Sep 21, 2029 ODE-409 Orphan Drug (7y) 3.2y
Sep 21, 2029 ODE* ODE* 3.2y
Sep 21, 2029 ODE-409 Orphan Drug (7y) 3.2y
Mar 27, 2028 PED Pediatric (6mo bonus) 1.7y
Mar 27, 2028 PED Pediatric (6mo bonus) 1.7y
Mar 27, 2028 PED Pediatric (6mo bonus) 1.7y
Mar 27, 2028 PED Pediatric (6mo bonus) 1.7y
Mar 27, 2028 PED Pediatric (6mo bonus) 1.7y
Mar 27, 2028 PED Pediatric (6mo bonus) 1.7y
Nov 29, 2027 PED Pediatric (6mo bonus) 1.4y
Nov 29, 2027 PED Pediatric (6mo bonus) 1.4y
Nov 8, 2027 PED Pediatric (6mo bonus) 1.3y
Nov 8, 2027 PED Pediatric (6mo bonus) 1.3y
Nov 8, 2027 PED Pediatric (6mo bonus) 1.3y
Nov 8, 2027 PED Pediatric (6mo bonus) 1.3y
Nov 8, 2027 PED Pediatric (6mo bonus) 1.3y
Nov 8, 2027 PED Pediatric (6mo bonus) 1.3y
Sep 27, 2027 M-312 Method (3y) 1.2y
Sep 27, 2027 M-312 Method (3y) 1.2y
Sep 27, 2027 M-311 Method (3y) 1.2y
Sep 27, 2027 M-312 Method (3y) 1.2y
Sep 27, 2027 M-312 Method (3y) 1.2y
Sep 27, 2027 M-311 Method (3y) 1.2y
Sep 27, 2027 M-311 Method (3y) 1.2y
Sep 27, 2027 M-312 Method (3y) 1.2y
Sep 27, 2027 M-311 Method (3y) 1.2y
Sep 27, 2027 M-311 Method (3y) 1.2y
Sep 27, 2027 M-312 Method (3y) 1.2y
Sep 27, 2027 M-311 Method (3y) 1.2y
May 29, 2027 NPP New Product (3y) 326d
May 29, 2027 NPP New Product (3y) 326d
May 8, 2027 ODE-301 Orphan Drug (7y) 305d
May 8, 2027 ODE-303 Orphan Drug (7y) 305d
May 8, 2027 ODE-302 Orphan Drug (7y) 305d
May 8, 2027 ODE-301 Orphan Drug (7y) 305d
May 8, 2027 ODE* ODE* 305d
May 8, 2027 ODE-302 Orphan Drug (7y) 305d
May 8, 2027 ODE-303 Orphan Drug (7y) 305d
May 8, 2027 ODE* ODE* 305d
May 8, 2027 ODE* ODE* 305d
May 8, 2027 ODE* ODE* 305d $LLY 1200.06 -1.14%
$LLY 1200.06 -1.14%
$LLY 1200.06 -1.14%
$LLY 1200.06 -1.14%
$LLY 1200.06 -1.14%
$LLY 1200.06 -1.14%
$LLY 1200.06 -1.14%
$LLY 1200.06 -1.14%
$LLY 1200.06 -1.14%
$LLY 1200.06 -1.14%
$LLY 1200.06 -1.14%
$LLY 1200.06 -1.14%
🐶 often sniffed alongside top 4 
comments(0)
5-min edit window · permanent after that